Arkolith/Insider Trading/MBII/Form 4

Helash Kevin

Chief Executive Officer, DirectorMARRONE BIO INNOVATIONS INC (MBII) · full profile →Form 4 · filed Jul 14, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 12, 2022Disposed to issuer(D)242K—$00

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 12, 2022Disposed to issuer(D)417K—$00
Jul 12, 2022Disposed to issuer(D)2.5M—$00

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-042211) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML